Loading...
Calcium-channel blockers (CCBs) relieve symptoms effectively in patients with stable angina, but short-acting CCBs have been associated with increased coronary and mortality risk in patients with coronary artery disease. Long-acting CCBs can reduce such risk in hypertensive patients, but what are their long-term effects in CAD patients?
In a manufacturer-sponsored multinational trial, 7665 patients with treated stable angina (mean age, 63.5; 80% men; 98% white; 52% hypertensive) were randomized to receive daily placebo or 60 mg of the long-acting CCB, nifedipine GITS (gastrointestinal therapeutic system). Subjects continued to take other medications that were prescribed by their physicians; at baseline, 86% were taking aspirin, 80% were taki…